Pharmaceuticals

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...

2023-04-25 13:46 2229

Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System

SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...

2023-04-25 08:42 2318

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational tri...

2023-04-24 21:00 2358

BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program

* Encouraging non-human primate (NHP) findings support the progression of IV-formulatedBMD-001 ahead of formal clinical studies for Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease * Further validation of Brain Targeting RNAi Nanomedicine (BTRiNTM), including target...

2023-04-24 20:00 1779

Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company

-The revenue from innovative drugs accounted for more than 65% of total revenue  -Simcere's total revenue and the revenue from innovative drugs hit record highs. NANJING, China, April 24, 2023 /PRNewswire/ -- On Apr. 18, Simcere Pharmaceutical (2096.HK) disclosed the latest progress on the compa...

2023-04-24 18:09 3004

Tibetan medicine advanced over past decade

BEIJING, April 24, 2023 /PRNewswire/ -- A news report from chinadaily.com.cn: Adhering to an equal emphasis on traditional Chinese and Western medicine, the government of the Tibet autonomous region has increased financial investment, formulated supportive policies and promoted the development of...

2023-04-24 17:04 1711

Samsung Biologics Reports First Quarter 2023 Financial Results

* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. * Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities. INCHEON, South Korea, April 24, 2023 /PRNews...

2023-04-24 14:51 2883

Patsnap Unveils Synapse Visitor, the Latest AI-Powered Pharmaceutical Intelligence Platform

LONDON, April 23, 2023 /PRNewswire/ -- On April 20, Patsnap, the world's leading SaaS provider for intelligence, announced the launch of its latest version of the intelligence platform, Synapse, available to visitors. This version includes advanced search functions for drugs and pharmaceutical o...

2023-04-24 08:00 3160

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr.Oliver Kong as Chief Medical Officer (CMO). Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall c...

2023-04-21 09:06 2630

CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer

SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CT041, an autologous CAR T-cell product candidate against the p...

2023-04-20 20:50 2927

Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics

* Implementation of Samyang Holdings' drug delivery technology for the development of mRNA-based cancer therapeutics SEOUL, South Korea, April 20, 2023 /PRNewswire/ -- Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement onThursday, April 20th, f...

2023-04-20 20:30 2454

Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-20 08:00 2349

500 women join Australia's landmark maternity medical device study

SYDNEY, April 19, 2023 /PRNewswire/ -- Medical device company Baymatob has successfully completed one ofAustralia's largest maternity health studies for a medical device, enrolling 500 mothers in a pilot study to evaluate its AI-guided labor monitoring device, Oli. The device is the only product ...

2023-04-19 21:08 2365

Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability

SUZHOU, China, April 19, 2023 /PRNewswire/ -- Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was recently granted the "Drug Manufacturing License" (C Certificate) by the Jiangsu Medical Products...

2023-04-19 21:00 2543

China Jo-Jo Drugstores Announces the Termination of the Previously Proposed Registered Direct Offering

HANGZHOU, China, April 19, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, announced today that the...

2023-04-19 20:30 3358

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

- Subjects in Herniorrhaphy Study Dosed - Successful FDA Interactions on Two Pre-clinical Pipeline Products Also Discussed SAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the re...

2023-04-19 11:05 1779

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.

2023-04-19 08:29 2100

Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate * Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDG...

2023-04-19 07:00 2358

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial

CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 sol...

2023-04-18 21:00 1752

GC Genome to Present the Brand New Liquid Biopsy Platform for Cancer Detection at AACR Annual Meeting 2023

YONGIN, South Korea, April 18, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the Americ...

2023-04-18 13:36 1944
1 ... 92939495969798 ... 153

Week's Top Stories